May 4, 2023 Expitope 3.0 presented at CIMT enables more comprehensive analysis of target antigens for TCR-T therapies
May 2, 2023 Medigene acquires worldwide, exclusive license of CD40L-CD28 Costimulatory Switch Receptor
April 27, 2023 Medigene to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)
April 24, 2023 Medigene presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers
April 18, 2023 New data presented at AACR shows enhanced T cell functionality of MDG1015 in solid tumors
April 11, 2023 Medigene to present Phase I clinical data for MDG1011 with poster presentation at EBMT 2023 Annual Meeting
April 4, 2023 Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development
April 3, 2023 Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute
March 28, 2023 Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston
March 20, 2023 Medigene AG Announces Appointment of Dr. Kirsty Crame, MD, as Head of Clinical Research & Development
March 16, 2023 Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting
February 23, 2023 Medigene presents first results for automated manufacturing of T cell receptor engineered T cells
February 1, 2023 Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications
